Welcome to our dedicated page for Compass Therapeutics SEC filings (Ticker: CMPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Compass Therapeutics, Inc. (Nasdaq: CMPX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage, oncology-focused biopharmaceutical issuer. Compass develops proprietary antibody-based therapeutics targeting the interplay between angiogenesis, the immune system, and tumor growth, and its filings offer detailed insight into this development activity, its financial position, and material corporate events.
Through Compass Therapeutics’ periodic reports, such as Forms 10-K and 10-Q, investors can review information on research and development expenses, general and administrative costs, cash and marketable securities, lease obligations, and other balance sheet items. These filings also describe the company’s pipeline of antibody-based product candidates, including tovecimig, CTX-8371, CTX-10726, and CTX-471, and outline the clinical and preclinical programs that support its oncology focus.
Current reports on Form 8-K provide more frequent updates on specific events. Recent 8-K filings have covered quarterly and year-to-date financial results, public equity offerings of common stock and pre-funded warrants, and an underwriting agreement related to a registered public offering. These documents describe the terms of financings, expected net proceeds, and stated uses of capital, such as funding research and clinical development, initial commercial readiness activities, and general corporate purposes.
On Stock Titan, users can view Compass Therapeutics’ SEC filings as they are made available through the EDGAR system and can use AI-powered summaries to interpret complex documents. These tools help explain key sections of lengthy filings, highlight important risk disclosures, and clarify how clinical trial progress, cash runway expectations, and capital-raising transactions are reflected in the company’s regulatory reports. In addition, users can track exhibits referenced in 8-K filings, such as underwriting agreements and forms of pre-funded warrants, to better understand the structure of Compass’s capital markets activities.
Compass Therapeutics, Inc. Chief Accounting Officer Neil Lerner reported an open-market purchase of common stock. On April 29, 2026, he bought 15,000 shares at $1.89 per share. Following this transaction, he directly holds 397,500 common shares.
His holdings include 62,500 unvested restricted stock units granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock and vests in four equal annual installments starting January 2, 2027.
Compass Therapeutics General Counsel Jonathan Anderman purchased 25,000 shares of common stock in an open-market transaction at $1.89 per share. After this buy, he directly holds 196,000 shares. 150,000 of these shares are unvested restricted stock units granted on January 2, 2026, which vest in four equal annual installments starting January 2, 2027, subject to service-based vesting conditions.
Compass Therapeutics, Inc. reported that its General Counsel, Jonathan Anderman, received a grant of 25,000 shares of common stock at an award value of $1.89 per share as equity compensation. Following this grant, he holds 196,000 shares in total.
The filing notes that 150,000 of these shares are unvested restricted stock units granted on January 2, 2026. Each RSU converts into one share of common stock if service-based vesting conditions are met, vesting in four equal annual installments starting January 2, 2027.
Lerner Neil reported acquisition or exercise transactions in this Form 4 filing.
Compass Therapeutics, Inc. Chief Accounting Officer Neil Lerner received a grant of 15,000 shares of common stock at $1.89 per share on April 29, 2026, increasing his direct holdings to 397,500 shares. A footnote notes that 62,500 of these shares are unvested restricted stock units granted on January 2, 2026, which vest in four equal annual installments starting January 2, 2027 under service-based conditions.
Compass Therapeutics has called its 2026 Annual Meeting for June 10, 2026 as a virtual-only event, open to stockholders of record as of April 15, 2026. Holders of 180,087,915 common shares may vote online, by phone, or by mail.
Stockholders will elect two Class III directors, vote on ratifying CohnReznick LLP as auditor for 2026, and cast non-binding advisory votes on 2025 executive pay and how often future “Say‑on‑Pay” votes should occur, with the board recommending an annual frequency.
The filing details board and committee structures, updated 2026 director retainers and option grants, and 2025 compensation for key executives, including total pay of $5.10 million for CEO Thomas J. Schuetz, $1.39 million for CFO Barry Shin, and $1.43 million for General Counsel Jonathan Anderman.
Compass Therapeutics reported detailed results from its randomized Phase 2/3 COMPANION-002 study of tovecimig plus paclitaxel in second-line biliary tract cancer. In 168 patients randomized 2:1, the combination improved overall response rate to 17.1% versus 5.3% for paclitaxel alone, meeting the primary endpoint with statistical significance (p=0.031).
The key secondary endpoint of median progression-free survival also favored tovecimig, with 4.7 months versus 2.6 months for control (hazard ratio 0.44, p<0.0001), based on blinded independent central review. Overall survival analyses did not meet statistical significance because 54% of control patients crossed over to receive tovecimig; these crossover patients showed median overall survival of 12.8 months versus 6.1 months for non-crossover patients (hazard ratio 0.54, p=0.04).
The company stated that tovecimig was generally well tolerated, with a safety profile consistent with prior studies, and noted that 85% of trial participants received the combination. Compass intends to meet with the U.S. FDA in the coming months to discuss the data in advance of a planned Biologics License Application submission for tovecimig in this setting.
Compass Therapeutics, Inc. files its annual report describing a clinical-stage oncology pipeline centered on antibody-based therapies targeting angiogenesis and immune checkpoints. The company highlights four clinical product candidates: tovecimig, CTX-471, CTX-8371 and CTX-10726.
Tovecimig, a DLL4 x VEGF-A bispecific, met the primary endpoint in a randomized Phase 2/3 biliary tract cancer trial, with a 17.1% overall response rate in combination with paclitaxel versus 5.3% for paclitaxel alone, and a statistically significant p-value of 0.031. Additional progression-free and overall survival data are expected in April 2026.
Monotherapy data in metastatic colorectal cancer showed a 5% response rate and 68% disease control. CTX-471, a CD137 agonist, produced responses in heavily pretreated patients and identified NCAM as a potential biomarker, with a Phase 2 basket study planned for mid-2026. CTX-8371, a PD-1 x PD-L1 bispecific, generated deep responses in a Phase 1 trial without dose-limiting toxicities, and expansion cohorts in NSCLC, TNBC and Hodgkin lymphoma are enrolling. CTX-10726, a PD-1 x VEGF-A bispecific, received FDA IND clearance and is entering a Phase 1 dose-escalation study.
Compass Therapeutics reported full-year 2025 results and a broad pipeline update. Net loss was $66.5 million, or $0.42 per share, compared with $49.4 million, or $0.36 per share, in 2024. Research and development expenses rose to $56.0 million, up 32%, mainly from higher manufacturing spend for tovecimig and CTX-10726.
As of December 31, 2025, cash and marketable securities totaled $209 million, up from $127 million a year earlier, giving an expected cash runway into 2028. The company used $49 million in operating cash during 2025, offset by $129 million in net proceeds from an underwritten public offering.
Clinically, lead asset tovecimig met the primary endpoint in the COMPANION-002 Phase 2/3 biliary tract cancer study, with progression-free survival and overall survival analyses expected in April. Expansion cohorts for CTX-8371, IND clearance and Phase 1 initiation for CTX-10726, and a planned Phase 2 trial for CTX-471 position 2026 as an important development year.
Compass Therapeutics, Inc. (CMPX) received an amended Schedule 13G from a group of Blackstone-related entities reporting a reduced ownership position. As of December 31, 2025, the reporting group beneficially owned an aggregate 6,126,182 shares of common stock, representing 3.4% of the class, based on 177,572,498 shares outstanding as of September 30, 2025. Blackstone Annex Master Fund L.P. directly holds 2,447,820 shares, and Spruce Street Aggregator L.P. directly holds 3,678,362 shares. The filing states that, as of that date, the reporting persons no longer beneficially own more than five percent of Compass Therapeutics’ common stock and describes this as an exit filing. The group also certifies that the securities were not acquired to change or influence control of the company and includes standard disclaimers that certain parties may be deemed beneficial owners only through their control of the direct holders.